Kintayl Capital has significantly reduced its stake in Core Scientific (CORZ), selling 495,390 shares during Q4 2025 for approximately $8.64 million. This move decreased their holdings from 6.3% to just 0.66% of their reportable assets under management, leaving them with 74,664 shares valued at $1.09 million. The sale comes as Core Scientific’s stock has surged 84% over the past year, outperforming the S&P 500’s 15% gain.
This transaction highlights a pivotal moment for Core Scientific, which is transitioning from self-mining to a more stable revenue model focused on colocation services. Despite a decline in revenue from $94.9 million to $79.8 million year-over-year, the company has seen improvements in gross profit and colocation revenue. Investors should note that while the stock’s performance has been strong, the underlying fundamentals suggest a cautious approach as the company navigates its shift in business strategy.
For market professionals, Kintayl’s divestiture signals a potential reevaluation of Core Scientific’s growth trajectory, emphasizing the importance of aligning investment positions with evolving company fundamentals.
Source: fool.com